Marshall Wace’s Filana Therapeutics FLNA Stock Holding History

Marshall Wace’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Sell	1,597,548 -414,995	-21%	-$591K	﹤0.01%	1894
2026 Q1	$3.4M	Sell	2,012,543 -102,764	-5%	-$212K	﹤0.01%	1506
2025 Q4	$4.19M	Buy	2,115,307 +54,021	+3%	+$173K	﹤0.01%	1236
2025 Q3	$6M	Buy	2,061,286 +1,989,572	+2,774%	+$4.58M	0.01%	1120
2025 Q2	$130K	Buy	+71,714	New	+$128K	﹤0.01%	2514
2025 Q1	–	Sell	-21,093	Closed	-$49.8K	–	3035
2024 Q4	$49.8K	Buy	+21,093	New	+$370K	﹤0.01%	2487
2023 Q3	–	Sell	-24,348	Closed	-$597K	–	2618
2023 Q2	$597K	Buy	+24,348	New	+$586K	﹤0.01%	1921
2022 Q4	–	Sell	-157,325	Closed	-$6.58M	–	3359
2022 Q3	$6.58M	Buy	+157,325	New	+$4.25M	0.01%	1180
2021 Q2	–	Sell	-195,942	Closed	-$8.81M	–	3030
2021 Q1	$8.81M	Sell	195,942 -211,864	-52%	-$8.33M	0.04%	530
2020 Q4	$2.78M	Buy	407,806 +387,866	+1,945%	+$3.46M	0.02%	804
2020 Q3	$230K	Buy	+19,940	New	+$89.9K	﹤0.01%	1429
2020 Q1	–	Sell	-54,669	Closed	-$284K	–	2005
2019 Q4	$284K	Buy	+54,669	New	+$94.4K	﹤0.01%	1288

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marshall Wace's FLNA Position: Q2 2026 in Review

Marshall Wace reduced its Filana Therapeutics (FLNA) stake by 21% in Q2 2026, selling an estimated $591K and leaving 1,597,548 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Marshall Wace first reported a position in FLNA in Q4 2019 and has held it in 12 quarters since. The position peaked at $8.81M in Q1 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Marshall Wace held 1,597,548 shares of Filana Therapeutics worth $1.9M as of Q2 2026.
Marshall Wace sold 414,995 Filana Therapeutics shares in Q2 2026, an estimated $591K.
Filana Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1894 holding.
Marshall Wace first reported a position in Filana Therapeutics in Q4 2019 and has held it in 12 quarters since.
Marshall Wace's Filana Therapeutics position peaked at $8.81M in Q1 2021.
84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.